All In Biotech

Drug Trial Radar · NCT06797297

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

A Phase II, Open-label, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal and Acral Melanoma Who Had Not Previously Received Systemic Therapy

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 203 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

203

Actual

Start

Feb 24, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label, randomized, multi-center study to assess the efficacy and safety of IBI363 monotherapy compared to Pembrolizumab in the treatment of patients with unresectable locally advanced or metastatic mucosal or acral melanoma who had not previously received systemic therapy.

Conditions

  • Melanoma

Interventions

  • IBI363Biological

    a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.

  • PembrolizumabBiological

    Pembrolizumab is a humanized monoclonal anti-PD1 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IRRC-Progression Free Survival(PFS)Time frame: up to 2 years

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Jishuitan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University Cancer Hospital & Institute, Beijing, China,

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Affiliated Tumor Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Hena, China

  • The Third people's hospital of Zhengzhou

    Zhengzhou, Henan, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangya Second Hospital of Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Baotou Cancer Hospital

    Baotou, Inner Mongolia, China

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Jiangxi Provincial Cancer Hospital

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The first hospital of Jilin University

    Changchun, Jilin, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Shandong First Medical University Affiliated Cancer Hospital

    Jinan, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

  • Second Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China

  • The Affiliated Cancer Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.